奥浦迈：拟14.51亿元购买澎立生物100%股权

Core Viewpoint - Aopu Mai plans to acquire 100% equity of Pengli Bio for a total transaction price of 1.451 billion yuan, aiming to enhance its client resources in preclinical research and expand its early-stage drug development pipeline [1] Group 1 - The acquisition will be executed through a combination of issuing shares and cash payments to 31 transaction parties, including PLHK and Jiaxing Huituo [1] - The transaction is expected to allow the company to promote its cell culture products and biopharmaceutical CDMO services to clients at an early stage of drug development [1] - This strategic move aims to broaden the company's potential customer base and secure innovative drug pipelines with promising commercialization prospects [1]